CELYAD ONCOLOGY SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.29 EUR | -4.76% |
|
-4.45% | -25.64% |
| 04-04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | - | Sales 2023 | 102K 111K 151K | Capitalization | 16.16M 17.56M 23.9M |
|---|---|---|---|---|---|
| Net income 2022 | -40M -43.47M -59.18M | Net income 2023 | -8M -8.69M -11.84M | EV / Sales 2022 | - |
| Net cash position 2022 | 12.19M 13.25M 18.03M | Net cash position 2023 | 5.95M 6.46M 8.8M | EV / Sales 2023 | 100 x |
| P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Celyad Oncology SA
More recommendations
More press releases
More news
| 1 day | -4.76% | ||
| 1 week | -4.45% | ||
| Current month | -10.77% | ||
| 1 month | -14.71% | ||
| 3 months | -22.25% | ||
| 6 months | -47.46% | ||
| Current year | -25.64% |
1 week
0.29
0.32
1 month
0.290.34
Current year
0.290.47
1 year
0.291.28
3 years
0.295.20
5 years
0.2918.50
10 years
0.2970.95
| Managers | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 0.29 | -4.76% | 45,854 |
| 24-05-15 | 0.3045 | -0.16% | 10,205 |
| 24-05-14 | 0.305 | -0.97% | 4,908 |
| 24-05-13 | 0.308 | -0.32% | 12,695 |
| 24-05-10 | 0.309 | -3.13% | 5,084 |
Real-time Euronext Bruxelles, May 16, 2024 at 11:27 am
More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
2024-09-20
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -25.64% | 13.71M | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- CYAD Stock
